Use of a murine monoclonal antibody which binds to malignant keratinocytes to detect tumor cells in microscopically controlled surgery

SummaryWe produced a murine monoclonal antibody, 7H2, and localized its epitope to one or more small regions on platelet glycoprotein (GP) Ilia. 7H2-IgG and 7H2-F(ab’)2 completely inhibit platelet aggregation and fibrinogen binding at low agonist concentrations, but only partially inhibit aggregation and fibrinogen binding at high agonist concentrations; 7H2-Fab has no effect on aggregation or fibrinogen binding at any agonist concentration. 7H2-IgG binds to the entire platelet population as judged by flow cytometry. At near saturating concentrations, ∼40,000 7H2-IgG antibody molecules bind per platelet. In contrast, ∼80,000 7H2 Fab molecules bind per platelet, suggesting that 7H2-IgG binding is bivalent. 7H2 was unable to inhibit fibrinogen binding to purified, immobilized GPIIb/IIIa. These data indicate that the bivalent binding of 7H2 to GPIIIa is required for its partial inhibition of fibrinogen binding to platelets, perhaps through dimerization of GPIIb/IIIa surface receptors (or more complex GPIIb/IIIa redistribution triggered by 7H2 binding) resulting in limited accessibility of fibrinogen to its binding site(s).

Download Full-text

High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: Broad implications for immunotherapy

Pediatric Blood & Cancer ◽

10.1002/pbc.20765 ◽

2007 ◽

Vol 48 (4) ◽

pp. 430-434 ◽

Cited By ~ 15

Author(s):

Brian H. Kushner ◽

Irene Y. Cheung ◽

Kim Kramer ◽

Shakeel Modak ◽

Nai-Kong V. Cheung

Keyword(s):

Monoclonal Antibody ◽

Immune Response ◽

Humoral Immune Response ◽

Murine Monoclonal Antibody ◽

High Dose ◽

Humoral Immune

Download Full-text

Presence and significance of NK cells in glioblastomas

Journal of Neurosurgery ◽

10.3171/jns.1989.70.5.0728 ◽

1989 ◽

Vol 70 (5) ◽

pp. 728-731 ◽

Cited By ~ 25

Author(s):

Jesús Vaquero ◽

Santiago Coca ◽

Santiago Oya ◽

Roberto Martínez ◽

Josefa Ramiro ◽

...

Keyword(s):

Monoclonal Antibody ◽

Nk Cells ◽

Survival Time ◽

Tumor Cells ◽

Lymphocytic Infiltration ◽

Surface Marker ◽

Content Type ◽

Hematoxylin And Eosin ◽

Hematoxylin And Eosin Staining ◽

Fine Print

✓ A monoclonal antibody against the surface marker IOT-10 of natural killer (NK) cells was used to investigate the presence of these cells in a series of 25 glioblastomas. In 40% of the tumors, IOT-10-positive NK cells were found in small numbers scattered among the tumor cells. The presence of IOT-10-positive NK cells was not related to the degree of lymphocytic infiltration in the tumor as demonstrated by hematoxylin and eosin staining, nor did it appear to influence the survival time of the patients studied.

Download Full-text

Characterization of a novel Le(x)-active ganglioside from chick intestinal tissues recognized by murine monoclonal antibody 188C1

Journal of Biological Chemistry ◽

10.1016/s0021-9258(18)99220-3 ◽

1991 ◽

Vol 266 (16) ◽

pp. 10268-10274 ◽

Cited By ~ 1

Author(s):

Y. Hirabayashi ◽

S.C. Fujita ◽

K. Kon ◽

S. Ando

Keyword(s):

Monoclonal Antibody ◽

Murine Monoclonal Antibody

Download Full-text

Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas

Blood ◽

10.1182/blood.v69.2.584.584 ◽

1987 ◽

Vol 69 (2) ◽

pp. 584-591 ◽

Cited By ~ 246

Author(s):

OW Press ◽

F Appelbaum ◽

JA Ledbetter ◽

PJ Martin ◽

J Zarling ◽

...

Keyword(s):

Monoclonal Antibody ◽

Lymph Node ◽

B Cell ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

B Cell Lymphomas ◽

Antigenic Modulation ◽

Minor Response ◽

High Doses ◽

Anti Cd20

Abstract Four patients with refractory malignant B cell lymphomas were treated with continuous intravenous (IV) infusions of murine monoclonal antibody (MoAb) 1F5 (anti-CD20) over five to ten days. Dose-dependent levels of free serum 1F5 were detected in all patients. Two patients had circulating tumor cells and in both cases 90% of malignant cells were eliminated from the blood stream within four hours of initiation of serotherapy. Antigenic modulation did not occur, and sustained reduction of circulating tumor cells was observed throughout the duration of the infusions. Serial bone marrow aspirations and lymph node biopsies were examined by immunoperoxidase and immunofluorescence techniques to ascertain MoAb penetration into extravascular sites. High doses (100 to 800 mg/m2/d and high serum 1F5 levels (13 to 190 micrograms/mL) were required to coat tumor cells in these compartments in contrast to the low doses that were adequate for depletion of circulating cells. Clinical response appeared to correlate with dose of MoAb administered with progressive disease (52 mg), stable disease (104 mg), minor response (1,032 mg), and partial response (2,380 mg) observed in consecutive patients. The patient treated with the highest 1F5 dose achieved a 90% reduction in evaluable lymph node disease, but the duration of this remission was brief (six weeks). This study demonstrates that high doses of 1F5 can be administered to patients with negligible toxicity by continuous infusion and that clinical responses can be obtained in patients given greater than 1 g of unmodified antibody over a ten-day period.

Download Full-text